Dermata Therapeutics, Inc. (NASDAQ:DRMAW) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMAW) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totaling 1,600 shares, a decrease of 38.5% from the August 31st total of 2,600 shares. Based on an average daily volume of 1,900 shares, the short-interest ratio is currently 0.8 days. Based on an average daily volume of 1,900 shares, the short-interest ratio is currently 0.8 days.

Dermata Therapeutics Stock Down 26.7%

DRMAW stock opened at $0.02 on Monday. The business has a 50-day moving average of $0.02 and a 200-day moving average of $0.02. Dermata Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.04.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.